Botanix Pharmaceuticals (ASX:BOT) gross sales of about AU$25 million from January through June for its Sofdra topical gel for excessive underarm sweating, missed expectations, and is a "very disappointing" outcome, according to a Thursday report by Euroz Hartleys.
Net revenue came in at AU$5 million, well below Euroz's AU$14.8 million estimate and AU$8.8 million market consensus, due to weaker script volumes and net pricing.
Despite the miss, key launch metrics were encouraging, with strong refill rates, rising prescriber numbers, and high adherence, Euroz said.
The company's 70% share price drop appears overdone, with the market pricing in minimal Sofdra success, Euroz added.
Euroz maintained Botanix's buy rating but lowered its price target to AU$0.40 from AU$0.80.
Shares of the company fell 4% on market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。